FDA product approval
approved product. Forzinity (elamipretide) has accelerated FDA approval for Barth syndrome in patients weighing at least 30 kg. This does not approve other uses or research products.
Longevity · compound · checked 2026-10-09
SS-31
SS-31 is listed here as a compound. Elamipretide acts on mitochondrial cardiolipin; product-specific evidence matters. Status was checked 2026-10-09. This card reports cited facts. It does not tell you to use SS-31 or how much to take.
Last checked Oct 9, 2026 by PepBear. Not medical advice.
- FDA product
- approved product
- Compounding
- not established
- Research
- product specific
- Sport
- unknown
What is SS-31?
Other names in the library: elamipretide, forzinity, SS-31 (10MG). The cited evidence and any approval concern the studied or labeled preparation. Oral, nasal, cosmetic and research-market versions do not inherit product approval or proven efficacy. Listed sizes: 10 mg. A seller title is a listing. It does not prove the vial matches a paper.
Elamipretide acts on mitochondrial cardiolipin; product-specific evidence matters.
Regulatory status, dated 2026-10-09
Compounding
not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.
Research
product specific. Barth syndrome patients meeting the approved Forzinity criteria; accelerated approval uses a surrogate endpoint.
Sport
unknown. Not individually verified; consult your sport authority.
What the cited papers actually measured
We mark the cited papers as B for Barth syndrome patients meeting the approved Forzinity criteria; accelerated approval uses a surrogate endpoint. and Approved labeled indication only.. Product-label clinical evidence. Risks on the record: Injection-site reactions were the most common adverse reactions reported with the approved Forzinity product. The approved product label warns about hypersensitivity; approval does not establish the safety or quality of research-market preparations.
We mark the cited papers as B. That is our label for how strong those papers are. It does not say the compound works.
How long it lasts, how you store it, listed sizes
The catalog does not record a single hour value. No verified human value is generalized here to research-labeled SS-31 products.
Half-life on file: no single hour value. No verified human value is generalized here to research-labeled SS-31 products. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.
U-100 math for listed SS-31 sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.
| Listed vial | 1 mL liquid | 2 mL liquid | 3 mL liquid |
|---|---|---|---|
| 10 mg | 100 | 50 | 33.3 |
Risks and mix-ups already on the record
- Injection-site reactions were the most common adverse reactions reported with the approved Forzinity product.
- The approved product label warns about hypersensitivity; approval does not establish the safety or quality of research-market preparations.
- Unknown or incomplete for research formulations; this is not a clearance for use.
- Unknown or incomplete; do not infer compatibility with medications or other substances.
People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.
Sources
- Primary evidence or regulator source · checked 2026-10-09
Questions people ask
Is SS-31 FDA-approved?
approved product. Forzinity (elamipretide) has accelerated FDA approval for Barth syndrome in patients weighing at least 30 kg. This does not approve other uses or research products.
Does PepBear pick an amount of SS-31?
The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.
Related cards
A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.